Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More

BioStorage Technologies, a provider of sample-management solutions for the bioscience industry, including storage, cold-chain logistics, and virtual sample intelligence, is expanding its services to the Asia Pacific region. The expansion includes the appointment of Jason Huang as general manager of the region. BioStorage Technologies Asia Pacific will be headquartered in Singapore and will provide technical consulting in addition to a range of sample-management capabilities. Huang will be responsible for overseeing and managing the operations in Asia, identifying and developing new services, and driving overall business development and services growth in the region. Read More

Bristol-Myers Squibb (BMS) has begun a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals. Upon the successful closing of the tender offer, stockholders of Amylin will receive $31.00 in cash for each share of Amylin common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable withholding taxes. Following the purchase of shares in the tender offer, Amylin will become a subsidiary of BMS. BMS had previously announced its intention to acquire Amylin on June 29, 2012. Read More

FDA has approved Gilead Sciences’s once-daily oral Truvada (emtricitabine; tenofovir disoproxil fumarate), a treatment to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. As part of the approval, Gilead worked with the FDA to develop a Risk Evaluation and Mitigation Strategy to help ensure safe use of Truvada for pre-exposure prophylaxis as part of a comprehensive prevention strategy. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More